Compounds > 2,6-dihydroxy-3-cyanopyridine
Page last updated: 2024-08-26

2,6-dihydroxy-3-cyanopyridine and emitefur

2,6-dihydroxy-3-cyanopyridine has been researched along with emitefur in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujii, S; Fukushima, M; Imaoka, T; Ohshimo, H; Shimamoto, Y; Shirasaka, T1
Fujii, S1
Hayashi, K; Imaoka, T; Kawaguchi, T; Kubo, M; Matsui, Y; Miyauchi, S; Utsunomiya, T1

Other Studies

3 other study(ies) available for 2,6-dihydroxy-3-cyanopyridine and emitefur

ArticleYear
Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
    Japanese journal of cancer research : Gann, 1989, Volume: 80, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Fluorouracil; Mice; Mice, Inbred ICR; Pyridines; Rats; Sarcoma 180; Sarcoma, Yoshida

1989
[BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Floxuridine; Fluorouracil; Liver; Mice; Pyridines; Pyrimidines; Rats; Sarcoma 180; Sarcoma, Experimental; Sarcoma, Yoshida; Tegafur; Uracil

1987
Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
    Japanese journal of cancer research : Gann, 1994, Volume: 85, Issue:6

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Combinations; Drug Interactions; Fluorouracil; Lung; Lung Neoplasms; Male; Neoplasm Transplantation; Pyridines; Rats; Sarcoma, Yoshida; Tegafur; Transplantation, Heterologous; Uracil

1994